Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Noven Therapeutics LLC

Division of Hisamitsu Pharmaceutical Co. Inc.
www.noven.com

Latest From Bridge Biotherapeutics

Deal Watch: Array Partners With Ono On Cancer Drugs In Japan, South Korea

French biotechs Servier and ILTOO sign an option agreement for the latter's IL-2 inhibitor for lupus, while Korean biotechs LegoChem and Bridge will team up in idiopathic pulmonary fibrosis.

Deals Business Strategies

Hanmi’s Case: One Failure Doesn’t Speak For All

Since Boehringer Ingelheim’s u-turn on its lung cancer partnership with Hanmi Pharmaceutical, the South Korean company has seen its stock prices falling and latterly a government investigation. Confidence in the country’s burgeoning drug development industry has taken a hit but there are still plenty of reasons to believe in the country’s R&D engine.

Research & Development South Korea

Venture Funding Deals, August 2016

Derived from Strategic Transactions, Informa's premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced June through July 2016.

Commercial Business Strategies

INTERVIEW: Bridge Chief On Pursuing NRDO, Global Ambitions

Bridge Biotherapeutics is off to a great start with its recent successful Series A funding, raising the largest amount so far for a South Korean bioventure. The company’s CEO talks to Scrip about where the company is heading including plans for its first-in-class inflammatory bowel disease candidate and further financings.

Research & Development Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Alias(es)
  • JDS Pharmaceuticals LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Hisamitsu Pharmaceutical Co. Inc.
  • Senior Management
  • Paul S Cartabiano, VP, Sales
    Scott Briggs, Dir., Mktg.
  • Contact Info
  • Noven Therapeutics LLC
    Phone: (305) 253-5099
    11960 SW 144th St.
    Miami, FL 33186
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register